Microbiome of the Lung and Respiratory Tract in HIV-Infected Individuals and HIV-Uninfected Controls (U01)

Post Date

December 4th 2008

Application Due Date

March 25th 2009

Funding Opportunity Number

RFA-HL-09-006

CFDA Number(s)

93.838

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $4000000

• Award Range:

  $None - $525000

Grant Description

Purpose.The National Heart, Lung, and Blood Institute (NHLBI) solicits grant applications under this Funding Opportunity Announcement (FOA) to characterize the microbiome of the lung (the airways and airspaces below the glottis and the lung parenchyma) alone or in combination with the nasal and/or oropharyngeal cavities in HIV-infected individuals and matched HIV-uninfected controls, including normal healthy controls, using molecular techniques to identify bacteria and if possible other organisms, e.g., viruses, cell-wall deficient organisms, protozoa, and fungi. Investigators should use high-throughput technology platforms to create a data set of sufficient quality and depth to allow analysis of how changes of microbiota relate to HIV lung disease progression/complications.These data will be used to examine the impact of changes in the respiratory microbiome on the pathogenesis and progression of HIV disease, on HIV-related respiratory complications, and the effects of anti-HIV therapies. The National Heart, Lung, and Blood Institute (NHLBI) invites applications for four Clinical/Sequencing research sites and one supporting Data Coordinating Center (DCC).Each application for a clinical/sequencing research site should propose approaches to characterize the lung microbiome and applicants are encouraged to include at least one hypothesis-driven mechanistic aim.Applicants must agree to collaborate with the other Clinical/Sequencing sites, the DCC, and projects funded under the Roadmap HMP program on overlapping areas of interest.Inclusion of the nasal and or pharyngeal cavities is optional.The Lung HIV Microbiome Program is designed to promote cooperation and coordination, facilitate scientific exchange, and leverage resources.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-09-006.html